Biodexa Pharmaceuticals Plc (BDRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in GBP.

Revenue Annual

0 250K 500K 750K 2019: 674K 2020: 343K 2021: 578K 2022: 699K 2023: 381K 2019 2020 2021 2022 2023

Gross Profit Annual

0 2.5M 5M 7.5M 2015: 1.3M 2016: 6.3M 2017: 6.7M 2015 2016 2017

Operating Income Annual

-10.5M -7M -3.5M 0 3.5M 7M 10.5M 2021: -7M 2022: -8.9M 2023: -8M 2024: -9.2M 2025: -8.6M 2021 2022 2023 2024 2025

Net Income Annual

-9M -6M -3M 0 3M 6M 9M 2021: -5.5M 2022: -7.7M 2023: -7.1M 2024: -5.7M 2025: -6.4M 2021 2022 2023 2024 2025

Cost of Revenue Annual

0 350K 700K 1.1M 2015: 70K 2016: 667K 2017: 926K 2015 2016 2017

Operating Cash Flow Annual

-15M -10M -5M 0 5M 10M 15M 2021: -6M 2022: -7M 2023: -6.8M 2024: -12.3M 2025: -5.6M 2021 2022 2023 2024 2025

Free Cash Flow Annual

-15M -10M -5M 0 5M 10M 15M 2021: -6.3M 2022: -7.1M 2023: -6.9M 2024: -12.3M 2025: -5.6M 2021 2022 2023 2024 2025

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20B 40B 60B 2021: 4M 2022: 4.9M 2023: 315.8M 2024: 5B 2025: 54.9B 2021 2022 2023 2024 2025

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.